6.7.13. guidelines systematic treatments castrate-resistant disease. summary statement mcrpc first line combination therapy: combination arpi plus parp inhibitors showed significant rpfs benefit rcts unselected patients. however, benefit mainly driven hrr- even pronounced brca 1/2- altered patients. far, clear os benefit seen, side effects parp inhibitors add substantial toxicity arpi monotherapy. therefore, recommendation given patients without hrr brca 1/2 -mutations data re-evaluated longer follow-up. recommendationsstrength ratingbase choice treatment performance status (ps), symptoms, comorbidities, location extent disease, genomic profile, patient preference, previous treatment hormone-sensitive metastatic pca (mhspc) (alphabetical order: abiraterone, cabazitaxel, docetaxel, enzalutamide, 177lutetium-psma-617-radioligand therapy, radium-223, sipuleucel-t, patients dna homologous recombination repair (hrr) alterations olaparib, olaparib/abiraterone, niraparib/abiraterone, rucaparib, talazoparib/enzalutamide).strongavoid sequencing androgen receptor targeted agents.weakoffer chemotherapy patients previously treated abiraterone enzalutamide.strongoffer patients metastatic castrate-resistant pca (mcrpc) candidates cytotoxic therapy chemotherapy naiive docetaxel 75 mg/m2 every three weeks.strongoffer patients previously untreated mcrpc harbouring hrr brca mutation abiraterone combination olaparib patient fit agents.strongoffer patients previously untreated mcrpc harbouring brca mutation abiraterone combination niraparib patient fit agents.strongoffer patients previously untreated mcrpc harbouring hrr-mutation enzalutamide combination talazoparib patient fit agents.strongoffer poly(adp-ribose) polymerase (parp) inhibitors pre-treated mcrpc patients relevant dna repair gene mutations.strongoffer patients mcrpc progression following docetaxel chemotherapy life-prolonging treatment options, include abiraterone, cabazitaxel, enzalutamide, radium-223 olaparib case dna homologous recombination repair (hrr) alterations.strongbase treatment decisions mcrpc ps, previous treatments, symptoms, comorbidities, genomic profile, extent disease patient preference.strongoffer abiraterone enzalutamide patients previously treated one two lines chemotherapy.strongoffer cabazitaxel patients previously treated docetaxel.strongoffer cabazitaxel patients previously treated docetaxel progressing within twelve months treatment abiraterone enzalutamide.strongoffer 177lu-psma-617 pre-treated mcrpc patients one metastatic lesions, highly expressing psma (exceeding uptake liver) diagnostic radiolabelled psma pet/ct scan.strong